Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Collin A Hovinga

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Expert Opinion on Investigational Drugs|October 22, 2002
Novel anticonvulsant medications in developmentCollin A Hovinga
Idrugs : the Investigational Drugs Journal|June 6, 2003
SPM-927 (Schwarz Pharma)Collin A Hovinga
Current Opinion in Investigational Drugs (London, England : 2000)|February 27, 2004
Valrocemide (Teva/Acorda)Collin A Hovinga
International Review of Neurobiology|October 22, 2008
Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokineticsPage B Pennell, Collin A Hovinga
International Review of Neurobiology|October 22, 2008
Antiepileptic drug therapy in pregnancy II: fetal and neonatal exposureCollin A Hovinga, Page B Pennell
Epilepsia|November 30, 2012
Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulationsIlo E Leppik, Collin A Hovinga
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Appropriateness of anticonvulsant concentration monitoring in hospitalized pediatric patientsCollin A Hovinga, Douglas F Rose, Stephanie J Phelps
Epilepsia|April 12, 2003
Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring unitsDavid V Lardizabal, Harold H Morris, Collin A Hovinga, et al.
Neurology|January 17, 2004
Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reactionDavid V Lardizabal, Hans O Lüders, Collin A Hovinga, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Chemical compatibility of depacon(®) with medications frequently administered by intravenous y-site delivery in patients with epilepsy or head traumaSahar M Rashed, Trevor W Sweatman, Laura Thoma, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Expert Opinion on Investigational Drugs|October 22, 2002
Novel anticonvulsant medications in developmentCollin A Hovinga
Idrugs : the Investigational Drugs Journal|June 6, 2003
SPM-927 (Schwarz Pharma)Collin A Hovinga
Current Opinion in Investigational Drugs (London, England : 2000)|February 27, 2004
Valrocemide (Teva/Acorda)Collin A Hovinga
International Review of Neurobiology|October 22, 2008
Antiepileptic drug therapy in pregnancy I: gestation-induced effects on AED pharmacokineticsPage B Pennell, Collin A Hovinga
International Review of Neurobiology|October 22, 2008
Antiepileptic drug therapy in pregnancy II: fetal and neonatal exposureCollin A Hovinga, Page B Pennell
Epilepsia|November 30, 2012
Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulationsIlo E Leppik, Collin A Hovinga
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Appropriateness of anticonvulsant concentration monitoring in hospitalized pediatric patientsCollin A Hovinga, Douglas F Rose, Stephanie J Phelps
Epilepsia|April 12, 2003
Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring unitsDavid V Lardizabal, Harold H Morris, Collin A Hovinga, et al.
Neurology|January 17, 2004
Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reactionDavid V Lardizabal, Hans O Lüders, Collin A Hovinga, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Chemical compatibility of depacon(®) with medications frequently administered by intravenous y-site delivery in patients with epilepsy or head traumaSahar M Rashed, Trevor W Sweatman, Laura Thoma, et al.
Pageof 3